ClinicalTrials.gg
TerminatedNCT05978804Updated Oct 21, 2026Results posted

Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease

An interventional study of Computerized Cognitive Training and Active tDCS (tDCS) on DLPFC in Mild Cognitive Impairment, Primary Progressive Aphasia and Dementia, sponsored by Johns Hopkins University. Terminated at 1 site in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Lack of funding
Updated Oct 21, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Cognitive Dysfunction by Johns Hopkins University — 13 open to participants now, 15 under way, 1 of them phase 3. Cognitive Dysfunction · Johns Hopkins University.

Enrollment
30th of 33
5 · median 52
Started
2023
with 6 others
No phase
22 of 34
8 open now
Registered
24th of 34
by date

Among the 34 studies in Cognitive Dysfunction by Johns Hopkins University, this one is the 30th largest by enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2023, is one of 22 with no phase, and was the 24th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

13 of the 34 studies in Cognitive Dysfunction by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Cognitive Dysfunction by Johns Hopkins University, or all of them as a file.
02

Study summary

The primary objective of this research is to evaluate the effects of non-invasive brain stimulation and computerized cognitive training on executive functioning in individuals with Primary Progressive Aphasia (PPA), mild cognitive impairment (MCI), or dementia. In this study, investigators will use transcranial direct current stimulation (tDCS) to stimulate the left dorsolateral prefrontal cortex (DLPFC). Previous studies have demonstrated that tDCS over the DLPFC led to improvements in attention deficit caused by stroke, Parkinson's Disease, and major depression as well as language deficits caused by neurodegenerative conditions such as primary progressive aphasia or mild cognitive impairment. The investigators seek to expand on this literature by investigating how anodal tDCS paired with and without cognitive training will impact executive functioning in PPA with Frontotemporal Dementia or Alzheimer's Disease pathology and Mild Cognitive Impairment/Alzheimer's Disease (e.g. shifting, updating, monitoring, and manipulation).

Read the detailed description

In this within-subject cross-over protocol, all participants will receive both, cognitive training and brain stimulation tDCS. Participants will be randomly assigned to begin with either cognitive training and brain stimulation (dual therapy) or just brain stimulation (monotherapy) and will receive the complementary therapy program in the second round of treatment. During each period of therapy, participants will receive 50 treatment sessions over the course of approximately 10 weeks. The computerized cognitive training and brain stimulation will both be preprogrammed to be done at home by the participant.

03

Conditions studied

  • Mild Cognitive Impairment
  • Primary Progressive Aphasia
  • Dementia
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Must be clinically diagnosed with PPA, fronto-temporal dementia (FTD), MCI or mild Alzheimer's disease (AD). Diagnosis will be based on neuropsychological testing, language testing (most commonly the Western Aphasia Battery), MRI, and clinical assessment.
  • Must be right-handed.
  • Must be proficient in English.
  • Must have a minimum high-school education.

Exclusion Criteria:

  • Uncorrected visual or hearing impairment by self-report.
  • Stroke/other premorbid neurological disorder affecting the brain.
  • Any other developmental language-based learning disorder other than PPA.
  • Inability to follow directions for baseline tasks.
  • Pre-existing psychiatric disorders such as behavioral disturbances, severe depression, and schizophrenia that do not allow them to comply or follow the study schedule and requirements such as repeated evaluation and therapy will be excluded.

Exclusion Criteria for MRI participation:

  • Severe claustrophobia.
  • Cardiac pacemakers or ferromagnetic implants.
  • Pregnant women.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Active tDCS on the DLPFC + Cognitive Intervention(s)

    Participants will receive active tDCS on DLPFC + Cognitive Intervention(s) first and then receive only active tDCS Intervention after a three-month washout period.

    Other: Computerized Cognitive Training · Device: Active tDCS (tDCS) on DLPFC

  • Experimental
    Active tDCS on the DLPFC only

    Participants will receive active tDCS on the DLPFC-only intervention first and then receive active tDCS + Cognitive Intervention(s) after a three-month washout period.

    Device: Active tDCS (tDCS) on DLPFC

Interventions

  • OtherComputerized Cognitive Training

    Computerized Cognitive training (BrainHQ or Constant Therapy)

  • DeviceActive tDCS (tDCS) on DLPFC

    Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.

06

What researchers measure

Primary outcomes

  1. Change in Language Composite Outcome

    A single language composite outcome will be generated by computing the mean of the percentage accuracy of the following naming, spelling, and sentence comprehension and repetition tasks: Boston Naming Test, Hopkins Action Naming Assessment, National Alzheimer's Coordinating Center Sentence Repetition. The investigators will calculate the percentage accuracy for each task and average them in order to get a composite score.

    Time frame: Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.

  2. Change in Executive Composite Outcome

    A single executive composite will be generated by computing the mean of the percentage accuracy of the tasks below reflecting new learning and memory, processing speed and executive functioning, attention and working memory, and verbal fluency respectively: Rey Auditory Verbal Learning Test, Digit Span, Category Fluency, and Verbal Fluency. The investigators will calculate the percentage accuracy for each task and average them in order to get a composite score.

    Time frame: Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.

  3. Change in Global Cognitive Scores

    This will be measured using the Montreal Cognitive Assessment (MoCA). Score range 0-30 points, higher is better.

    Time frame: Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.

Secondary outcomes

  1. Change in Working Memory Capacity.

    This will be measured using Digit Span Backward for verbal working memory. The digit span backward is a well-established task that assesses rote immediate verbal memory and working memory. Participants are presented with a series of digits and are instructed to repeat the digits in the reverse order. Scoring is based on the number of digits shown in a trial (i.e. 1,7 is 2 digits). There are two trials for each span, and if both trials are correct, the score is a whole number (i.e. 2). If one trial is incorrect in a span, subtract 0.5 from that tier (i.e. 1.5). Increase in score from before to after intervention is considered a benefit. The range of the score is from 0 to 8, with 0 being the lowest/worst score and 8 being the highest/best score possible.

    Time frame: Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.

07

Results

Posted Oct 21, 2026

Participant flow

Intervention Phase 1 (10 Weeks)
Participant flow — Intervention Phase 1 (10 Weeks)
MilestoneActive tDCS on the DLPFC + Cognitive Intervention, FirstActive tDCS on the DLPFC-only, First
Started50
Completed50
Not completed00
Washout (3 Months)
Participant flow — Washout (3 Months)
MilestoneActive tDCS on the DLPFC + Cognitive Intervention, FirstActive tDCS on the DLPFC-only, First
Started50
Completed30
Not completed20
Withdrew: Lost to follow-up20
Intervention Phase 2 (10 Weeks)
Participant flow — Intervention Phase 2 (10 Weeks)
MilestoneActive tDCS on the DLPFC + Cognitive Intervention, FirstActive tDCS on the DLPFC-only, First
Started30
Completed00
Not completed30
Withdrew: Withdrawal by subject30

Outcome measures

PrimaryChange in Language Composite Outcome

A single language composite outcome will be generated by computing the mean of the percentage accuracy of the following naming, spelling, and sentence comprehension and repetition tasks: Boston Naming Test, Hopkins Action Naming Assessment, National Alzheimer's Coordinating Center Sentence Repetition. The investigators will calculate the percentage accuracy for each task and average them in order to get a composite score.

Time frame:
Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
Reported as:
Mean · Percentage accuracy
Change in Language Composite Outcome
Percentage accuracyActive tDCS on the DLPFC + Cognitive Intervention(s)
Change in Language Composite Outcome-0.54 ± 11.39
PrimaryChange in Executive Composite Outcome

A single executive composite will be generated by computing the mean of the percentage accuracy of the tasks below reflecting new learning and memory, processing speed and executive functioning, attention and working memory, and verbal fluency respectively: Rey Auditory Verbal Learning Test, Digit Span, Category Fluency, and Verbal Fluency. The investigators will calculate the percentage accuracy for each task and average them in order to get a composite score.

Time frame:
Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
Reported as:
Mean · Percentage accuracy
Change in Executive Composite Outcome
Percentage accuracyActive tDCS on the DLPFC + Cognitive Intervention(s)
Change in Executive Composite Outcome-2.33 ± 5.02
PrimaryChange in Global Cognitive Scores

This will be measured using the Montreal Cognitive Assessment (MoCA). Score range 0-30 points, higher is better.

Time frame:
Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
Reported as:
Mean · score on a scale
Change in Global Cognitive Scores
score on a scaleActive tDCS on the DLPFC + Cognitive Intervention(s)
Change in Global Cognitive Scores-1.33 ± 4.16
SecondaryChange in Working Memory Capacity.

This will be measured using Digit Span Backward for verbal working memory. The digit span backward is a well-established task that assesses rote immediate verbal memory and working memory. Participants are presented with a series of digits and are instructed to repeat the digits in the reverse order. Scoring is based on the number of digits shown in a trial (i.e. 1,7 is 2 digits). There are two trials for each span, and if both trials are correct, the score is a whole number (i.e. 2). If one trial is incorrect in a span, subtract 0.5 from that tier (i.e. 1.5). Increase in score from before to after intervention is considered a benefit. The range of the score is from 0 to 8, with 0 being the lowest/worst score and 8 being the highest/best score possible.

Time frame:
Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
Reported as:
Mean · score on a scale
Change in Working Memory Capacity.
score on a scaleActive tDCS on the DLPFC + Cognitive Intervention(s)
Change in Working Memory Capacity.0 ± 0.61

Adverse events

Collected over From enrollment until end of follow-up, up to 5 months post end of intervention of phase 1, up to 40 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active tDCS on the DLPFC + Cognitive Intervention(s)0/5 (0%)0/5 (0%)0/5 (0%)
Active tDCS on the DLPFC Only———

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants
Mean64.2 ± 1.79
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female3
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White5
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Sep 2025, 25 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Aug 7, 2023
StartActual
Aug 10, 2023
Primary completionActual
Sep 10, 2025
CompletionActual
Sep 10, 2025
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Enrollment
36→5
Oct 21, 2026
Primary outcomes
1 edited, 2 time frame changed, 2 description edited
What changed in the outcomes
  • EditedChange in language composite outcomeLanguage Composite OutcomeTime frame: Before intervention, immediately after intervention → Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
  • Time frameChange in Executive Composite OutcomeBefore intervention, immediately after intervention → Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
  • Time frameChange in Global Cognitive ScoresBefore intervention, immediately after intervention → Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
  • DescriptionChange in Executive Composite Outcome: how it is measured was reworded
  • DescriptionChange in Global Cognitive Scores: how it is measured was reworded
Oct 21, 2026
Documents
Secondary outcomes
1 edited, 2 removed
What changed in the outcomes
  • EditedChange in working memory capacityWorking Memory Capacity.Time frame: Before intervention, immediately after intervention → Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
  • RemovedChange in Selective attention and cognitive flexibilityTime frame: Before intervention, immediately after intervention
  • RemovedChange in attention and task switchingTime frame: Before intervention, immediately after intervention
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Results posted
    Enrollment 36→5
    Primary outcomes 1 edited, 2 time frame changed, 2 description edited
    What changed in the outcomes
    • EditedChange in language composite outcomeLanguage Composite OutcomeTime frame: Before intervention, immediately after intervention → Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
    • Time frameChange in Executive Composite OutcomeBefore intervention, immediately after intervention → Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
    • Time frameChange in Global Cognitive ScoresBefore intervention, immediately after intervention → Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
    • DescriptionChange in Executive Composite Outcome: how it is measured was reworded
    • DescriptionChange in Global Cognitive Scores: how it is measured was reworded
    Secondary outcomes 1 edited, 2 removed
    What changed in the outcomes
    • EditedChange in working memory capacityWorking Memory Capacity.Time frame: Before intervention, immediately after intervention → Up to 6 weeks before intervention (before Phase 1) up to 1 week post-intervention (after Phase 1). Phase 1 intervention lasted 10 weeks.
    • RemovedChange in Selective attention and cognitive flexibilityTime frame: Before intervention, immediately after intervention
    • RemovedChange in attention and task switchingTime frame: Before intervention, immediately after intervention
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05978804
Collaborators
Ybrain Inc.
Responsible party
Sponsor
First posted
Aug 7, 2023
Start date
Aug 10, 2023
Primary completion
Sep 10, 2025
Completion
Sep 10, 2025
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

Kyrana Tsapkini, PhD
principal investigator · Johns Hopkins University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion